Description, Causes and Risk Factors:
Myelogenous leukemia is a fast-growing cancer of the blood and bone marrow. In myelogenous leukemia, the bone marrow makes many unformed cells called blasts. Blasts normally develop into white blood cells [WBCs] that fight infection. However, the blasts are abnormal in myelogenous leukemia. They do not develop and cannot fight infections. The bone marrow may also make abnormal red blood cells [RBCs] and platelets. The number of abnormal cells (or leukemia cells) grows quickly. They crowd out the normal red blood cells, white blood cells and platelets the body needs.
More than 25000 new cases occur in The United States each year, mostly in elderly people. The average age of a person with myelogenous leukemia is 65 years. Fewer than 10% of people with myelogenous leukemia are children.
Hematopoiesis in normal cells involves the differentiation of a stem cell into myelocytes, lymphocytes, and megakaryocytes. In myelogenous leukemia, this process of cell differentiation is interrupted in those cells committed to the myeloid lineage. Some reports have supported the concept of a single transformed hematopoietic stem cell, whereas others have contended that transformation can occur at any point from stem cell to lineage-committed progenitor cell. This transformation can occur either as a de novo event or associated with previous therapy.
Several molecular and genetic lesions have been identified in myelogenous leukemia, leading to advances in defining its pathogenesis. The most familiar of these is the t(15;17) translocation, resulting in myelogenous leukemia with abnormal promyelocytes, known as acute promyelocytic leukemia (APL). Translocation of these chromosomes results in the fusion of the retinoic acid receptor gene alpha on chromosome 15, with the PML gene on chromosome 17, giving rise to a fusion product that prevents differentiation to mature granulocytes. This block in differentiation can be overcome with all-trans retinoic acid (ATRA), a vitamin A derivative. The DNA-binding subunit core-binding factor b (CBFb) produces a transcription factor that regulates numerous hematopoietic-specific genes. The genetic translocations t(8;21), inv(16), and t(16;16) have all been associated with this transcription factor. Myelogenous leukemia patients with these genetic disorders have a better prognosis. Six percent to 8% of patients with myelogenous leukemia have structural alterations of 11q23, leading to the MLL rearrangement. The MLL gene rearrangement, also known as mixed lineage leukemia, may lead to myelogenous leukemia composed of both myeloid and lymphoid cells. The MLL gene rearrangement portends a worse outcome in patients with acute myelogenous leukemia.
Causes & Risk Factors:
Germline mutations in the AML-1 gene are known to be associated with an increased risk of the development of acute myelogenous leukemia. Additionally, congenital immunodeficiency disorders. including infantile X-linked agammaglobulinemia and Down syndrome, have also been associated with an increased incidence of acute myelogenous leukemia.
Several studies demonstrate a relationship between radiation exposure and acute myelogenous leukemia. Early radiologists (before the use of appropriate shielding) were found to have an increased likelihood of developing leukemia. Patients receiving therapeutic irradiation for ankylosing spondylitis were at increased risk of acute myelogenous leukemia. Survivors of the atomic bomb explosions in Japan were at a markedly increased risk for the development of leukemia. Persons who smoke have a small but statistically significant (odds ratio, 1.5) increased risk of developing acute myelogenous leukemia. In several studies, the risk of myelogenous leukemia was slightly increased in people who smoked compared with those who did not smoke. Exposure to benzene is associated with aplastic anemia and pancytopenia. These patients often develop acute myelogenous leukemia. Many of these patients demonstrate M6 morphology.
Myelogenous leukemia can affect both children and adults.
Chromosomal instability in several autosomal dominant conditions can lead to acute myelogenous leukemia, including Fanconi's anemia, ataxia-telangiectasia, neurofibromatosis, and Bloom's syndrome.
Myelogenous leukemia is more commonly diagnosed in developed countries, and it is more common in Whites mainly (Americans, Australians, & Europeans) than in other populations.
The symptoms of myelogenous leukemia are caused by low numbers of healthy blood cells and high numbers of leukemia cells.
Red blood cells [RBCs] carry oxygen throughout the body. Low numbers of RBCs can lead to anemia — feeling tired or weak, being short of breath and looking pale are the most common symptoms.
Platelets control bleeding. Low numbers platelets can lead to easy bleeding or bruising and tiny red spots under the skin (petechiae).
High numbers of leukemia cells may cause pain in the bones or joints.
White blood cells [WBCs] fight infection. Low numbers of WBCs can lead to fever and frequent infections.
Other General Symptoms:
A large number of infections over a short period.
Breathlessness (shortness of breath).
Hyperhidrosis (sweating a lot).
Easy skin bruising.
Swollen lymph nodes (glands).
Unexplained regular bleeding, of perhaps the nose or gums.
If the affected cells get into the central nervous system (CNS) there may be headaches, blurred vision, dizziness, fits (seizures) and vomiting.
A high fever.
Blood studies: Which generally may include, but not limited to,
Peripheral blood smear.
Blood chemistry profile.
Blood culture.Appropriate cultures should be obtained in patients with fever or signs of infection, even in the absence of fever.
Complete blood count (CBC).
Perform human leukocyte antigen (HLA) or DNA typing in patients who are potential candidates for allogeneic transplantation.
Bone marrow aspiration & biopsy.
Imaging studies: Imaging studies generally needed as precautionary measures, which may include chest radiograph, electrocardiography, MUGA scanning, etc.
Myelogenous leukemia treatment has two phases, Induction Therapy and Post-remission Therapy (continuation therapy). Treatment will be done under supervision of Multidisciplinary Approach especially Hematologist and Oncologist.
Post-Remission Therapy - the aim is to destroy any leukemic cells that may still linger. This involves high doses of chemotherapy, with a combination of the following medications: cytarabine, cyclophosphamide, idarubicin, etoposide, daunorubicin, mitoxantrone, or cytarabine.
Induction Therapy - the aim is to destroy as many leukemia cells as possible and achieve remission. The following drugs may be used: idarubicin, daunorubicin, or mitoxantrone +cytarabine & thioguanine. As soon as all signs of leukemia are gone (remission), the patient enters the second phase.
Patients should limit their activity to what is tolerable. They should refrain from strenuous activities (eg, lifting, exercise).
NOTE: The above information is educational purpose. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition.
DISCLAIMER: This information should not substitute for seeking responsible, professional medical care.
A new study, conducted by the scientists from the University of Gothenburg in Sweden, finds that light and moderate physical activity, for example walking and swimming, may help reduce the stroke severity. The study included approximately data from 1,000 individuals...
According to the latest study, published in the European Journal of Public Health, regular use of probiotics may cut the necessity for antibiotics and help decrease the rise of antibiotic resistance. Having performed the analysis of the data, collected from recent...
It is very entertaining to be a sport fan. There is a big variety of sport games that are extremely interesting to follow. Moreover, it is always fun to anticipate the score and watch the enthusiasm live. One of the benefits of being sports fan is using different...read more
A new study of nearly 18,000 participants found that those with high fitness at middle age were significantly less likely to die from heart disease in later life, even if they were diagnosed with depression. Doctor's Tips: How to Stay Fit While Treating Depression Dr....read more
The warm ups are supposed to increase body temperature and blood flow so the muscles and surrounding joints become more responsive and prepared for physical activity. Although there’s a neurological element to warm-ups, most research focuses on the physiological...read more